euro adhoc: Marseille-Kliniken AG / Financial Figures/Balance Sheet / - Revenues extended to EUR 214.8 million in financial year 2006/2007 - Gains per share DVFA/SG increased by EUR 0.10 to EUR 0.86 -

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

annual report

10.10.2007

Berlin, October 10., 2007. Marseille-Kliniken AG (Prime Standard,
ISIN DE 0007783003, and MKA) continues to grow and improves its
result. On the basis of preliminary and audited figures for the
fiscal year 2006/07, the Marseille-Kliniken AG was able to expand
revenues to EUR 214.8 million (previous year: EUR 210.4 million). The
group´s annual surplus based on minority shares climbed from EUR 8.9
million to EUR 9.1 million. This translates into a per- share profit
of EUR 0.75 compared to EUR 0.73 in the year prior. The EBIT came in
at EUR 23.6 million. In 2005/06 it had been at a level of EUR 25.8
million. The EBITDAR result was 69.8 million Euro in the financial
year compared to 66.7 million Euro the previous year. The balance
sheet reported equity capital totals EUR 71.2 million instead of last
year´s EUR 66.8 million so that the equity capital quota is now 23.0
% (year prior 20.7 %).

The DVFA/SG (IFRS) adjusted result this reporting period came in at
EUR 10.5 million versus EUR 9.3 million last year. Per share, this
equals a profit increase of EUR 0.10 to EUR 0.86 (2005/06 = EUR
0.76). Compared to last year´s EUR 58.0 million, the EBITDAR could be
increased to EUR 61.8 million and the EBIT to EUR 20.2 million (year
prior: EUR 19.4).

The care sector operated 53 facilities with a bed capacity of 7,287
(previous year 7,134 beds) by the end of the year. Its revenues were
extended from EUR 162.7 million to 166.5 million during the reporting
period. Due to a one-time special tax impact in the amount of EUR 0.5
million, which resulted from the sale and lease back transaction, the
DVFA result declined slightly from EUR 12.9 million in 2005/06 to EUR
12.7 million. On par with the forecast, bed capacity utilization
could be continuously expanded per quarter from last year´s average
91.6 %. to an average of 92.8 % by the the fiscal year. The total bed
capacity of the group was expanded to 8,765 beds. Group capacity
utilization outperformed last year´s and rose to 89.7 % from 88.2 %.

The rehabilitation segment continued to see planned reductions.
During the reporting period, the bed capacity dropped from 1,569 beds
last year to now 1,478 beds at a total of 10 facilities. In
conjunction with this development, the capacity utilization quota for
the year overall could be increased. The quota rose from last year´s
74.2 % to 75.9 % in FY 2006/07. Revenues also improved in the
rehabilitation segment - from EUR 47.7 million to 48.3 million during
the reporting period. The DVFA/SG-result (IFRS) was improved and came
in at EUR -2.2 million (EUR -3.6 million in 2005/06). This represents
an increase of 1.4 million thanks to the higher capacity utilization
quota.

The company anticipates that it will continue to enjoy positive
effects in its business divisions during the current fiscal year. The
capacity reduction in the rehabilitation area translated into a
significant increase of capacity utilization to approximately 87 %
(previous year 76.7 %) even during the first quarter. The expansion
in patient care continues at a rapid pace. In the first few months of
the new fiscal year, the company has added 310 beds to the network
and has again achieved substantial boosts in the capacity utilization
quota of its existing facilities to 93.7 % in the first quarter (year
prior 92.6 %). In the current fiscal year, thanks to additional
capacities in the care segment and the occupancy rates of the
existing bed capacity in both divisions - care and rehabilitation - ,
the company anticipates a substantial boost in revenues to EUR 240.0
million and a before-adjustments EBIT of EUR 24.0 million. Due to
corporate tax reforms, latent tax accrual that had been accumulated
in the past for a total of EUR 4.5 million could be liquidated to
affect the statement net income. The result after taxes will amount
to at least EUR 18 million.

In the new fiscal year 2007/2008, the care concept in the 2-star
segment and the expansion of "Assisted Living" will be the focus of
the expansion strategy. The company continues to remain committed to
its growth goal of attaining a contractually vested total bed
capacity of 12,000 by end of 2008.

End of the ad hoc release

end of announcement euro adhoc 10.10.2007 07:34:41
--------------------------------------------------------------------------------

ots Originaltext: Marseille-Kliniken AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Marseille-Kliniken AG
Axel Hölzer
CEO
Alte Jakobstraße 79/80
10709 Berlin, Germany
Tel.: +49-30/24632-400
Fax: +49-30/24632-401
www.marseille-kliniken.com

Hillermann Consulting
Christian Hillermann
Investor Relations Marseille-Kliniken AG
Poststraße 14/16
20354 Hamburg, Germany
Tel.: +49-40/320279-10
Fax: +49-40/320279-14
www.hillermann-consulting.com

Branche: Pharmaceuticals
ISIN: DE0007783003
WKN: 778300
Index: CDAX, Classic All Share, Prime All Share
Börsen: Börse Frankfurt / official dealing/prime standard
Börse Berlin / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hamburg / official dealing